2030年亚太肌少症治疗市场规模、份额及分析

亚太地区肌肉减少症治疗市场分析及规模

推动亚太地区肌肉减少症治疗市场增长的主要因素是肌肉减少症患病率的上升。此外，人们对肌肉减少症及其对健康的不利影响的认识不断提高是推动市场增长的另一个关键因素。营养不良和久坐不动等生活方式因素也会影响市场。然而，缺乏标准化诊断以及治疗和干预的高成本预计将抑制市场增长。

Data Bridge Market Research 分析，亚太地区肌肉减少症治疗市场预计到 2030 年将达到 861,882.42 万美元的价值，预测期内复合年增长率为 5.9%。本市场报告还深入介绍了定价分析和技术进步。

报告指标	细节
预测期	2023 至 2030 年
基准年	2022
历史岁月	2021（可定制为 2015 - 2020）
定量单位	收入（千美元）、销量（单位）、定价（美元）
涵盖的领域	治疗类型（药物、维生素/膳食补充剂等）、类型（原发性肌肉减少症和继发性肌肉减少症）、阶段（前期肌肉减少症、肌肉减少症和重度肌肉减少症）、给药途径（口服、注射等）、性别（男性和女性）、最终用户（医院、专科诊所、家庭医疗保健等）、分销渠道（直接招标、零售等）
覆盖国家	日本、澳大利亚、印度、中国、韩国、新西兰、新加坡、泰国、马来西亚、越南、台湾、印度尼西亚、菲律宾和亚太地区其他地区
涵盖的市场参与者	雅培、雀巢健康科学（雀巢公司的子公司）、诺华公司、赛诺菲、Haleon 集团、巴斯夫欧洲公司、帝斯曼、Fermenta Biotech Limited、AstaReal Co., Ltd.、Metagenics、BioThrive Sciences.、Wellona Pharma、The Vitamin Company India、Biogen SA、Healing Pharma India Pvt. Ltd. 等

市场定义

肌肉减少症治疗是指与旨在预防、管理或治疗肌肉减少症的产品和服务相关的商业领域。肌肉减少症是一种与年龄有关的渐进性疾病，其特征是骨骼肌质量、力量和功能的丧失，通常始于 30 岁左右，并在 60 岁后加速。肌肉减少症对个人的整体健康和生活质量有重大影响。肌肉力量和耐力也会相应下降，随着肌肉质量的下降，日常任务变得更具挑战性，跌倒和骨折的风险也会增加。此外，肌肉减少症还会导致代谢变化、胰岛素抵抗和肥胖可能性增加。

亚太地区肌肉减少症治疗市场动态

本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：

驱动程序

肌肉减少症患病率上升

肌肉减少症是一种以肌肉质量、力量和功能下降为特征的疾病，尤其发生在老年人身上。随着年龄的增长，老年人的肌肉质量和功能会逐渐下降，这导致他们容易患上肌肉减少症。随着世界人口老龄化，患上肌肉减少症的人数正在稳步增加。这种人口结构的变化直接推动了对肌肉减少症治疗方案的需求。该病的患病率不断上升意味着需要诊断和治疗的人数越来越多，从而为肌肉减少症治疗市场创造了更大的患者群体。

随着医疗保健和医学的进步，人们的寿命越来越长。然而，随着年龄的增长，人们患上肌肉减少症的可能性也越来越大。这种较长的预期寿命导致该病的总体患病率上升。糖尿病、心血管疾病和癌症等慢性疾病会导致肌肉损失并导致肌肉减少症的发生。这些疾病发病率的上升直接影响了肌肉减少症患病率的上升。

人们对肌肉减少症及其对健康的有害影响的认识不断提高

人们对肌肉减少症及其对健康的有害影响的认识不断提高，这是医疗保健和老龄化领域的重大发展。与肌肉减少症相关的研究和出版物显著增加。科学研究、医学期刊和出版物为医疗保健专业人员提供了有关该病的患病率、诊断和后果的宝贵信息。医学院和培训项目已将肌肉减少症纳入课程。这确保医疗保健专业人员（包括医生、护士和理疗师）接受有关肌肉减少症、其风险因素和管理策略的教育。

各种倡导团体和组织一直在积极提高人们对肌肉减少症的认识。这些团体经常与医疗保健专业人员合作，向公众宣传这种疾病的风险以及早期诊断和干预的重要性。肌肉减少症在主流媒体中得到了越来越多的报道，包括文章、新闻报道和纪录片。这种曝光有助于提高公众的认识。

机会

市场参与者的战略举措

肌肉减少症治疗市场正在经历大幅增长，因为它是一种与年龄有关的渐进性疾病，其特征是肌肉质量、力量和功能的丧失。这是一个重大的健康问题，尤其是对老年人来说，因为它会导致行动能力下降、跌倒和骨折风险增加以及整体生活质量下降，因此主要市场参与者正在积极采取战略举措进行产品开发。从而为市场扩张和发展开辟了机会。

战略计划包括与研究机构、医疗保健组织和学术中心的合作和伙伴关系。市场参与者可以利用他们的知识和资源，通过与该领域的专家合作来加速肌肉减少症治疗的开发和商业化。此类合作促进了知识交流、接触临床试验患者群体以及汇集专业知识以推动市场创新。

克制/挑战

缺乏标准化诊断

医疗保健专业人员可能不会定期筛查该疾病，尤其是成年人，这可能会妨碍早期干预和治疗。如果没有标准化的诊断，医疗保健提供者可能会使用不同的标准和方法来识别肌肉减少症。这种不一致可能导致肌肉减少症的患病率和确诊病例数存在差异，因此很难评估真正的市场规模和治疗需求。

肌肉减少症是一种多方面的疾病，会根据年龄、性别和合并症等因素对个体产生不同的影响。患者群体可能各不相同，因此，如果没有标准化的诊断标准，就很难进行临床试验和研究以准确评估治疗效果。肌肉减少症治疗的临床试验可能使用不同的诊断标准，因此很难比较不同研究的结果。这种标准化的缺乏可能会阻碍监管机构开发和批准新的治疗方法。

最新动态

2023 年 9 月，Biophytis 获得 FDA（食品和药物管理局）授权在美国启动其 SARA-31 研究，这是有史以来首个针对肌肉减少症的 3 期研究。这将有助于该组织增加其产品组合和品牌形象。
2023 年 8 月，亚太地区消费者健康领域的领导者 Haleon 和人道主义援助组织 Direct Relief 宣布，双方已达成多年期承诺，旨在扩大服务不足社区的日常医疗服务，同时加强全球应急响应和准备工作。这将提升该公司在其他品牌中的品牌形象。

亚太地区肌肉减少症治疗市场范围

亚太地区肌肉减少症治疗市场根据治疗类型、类型、阶段、给药途径、性别、最终用户和分销渠道分为七个显著的细分市场。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

治疗类型

药物
维生素/膳食补充剂
其他的

根据治疗类型，市场分为药物、维生素/膳食补充剂和其他。

类型

原发性肌肉减少症
继发性肌肉减少症

根据类型，市场分为原发性肌肉减少症和继发性肌肉减少症。

阶段

肌肉减少症前期
肌肉减少症
严重肌肉减少症

根据阶段，市场分为肌少症前期、肌少症和重度肌少症。

给药途径

口服
注射剂
其他的

根据给药途径，市场分为口服、注射和其他。

性别

男性
女性

根据性别，市场分为男性和女性。

最终用户

医院
家庭医疗保健
专科诊所
其他的

根据最终用户，市场分为医院、家庭医疗保健、专科诊所和其他。

分销渠道

直接招标
零售销售
其他的

根据分销渠道，市场分为直接招标、零售和其他。

亚太地区肌肉减少症治疗市场区域分析/见解

根据治疗类型、类型、阶段、给药途径、性别、最终用户和分销渠道，亚太地区肌肉减少症治疗市场分为七个显著的部分。

本市场报告涵盖的国家包括日本、澳大利亚、印度、中国、韩国、新西兰、新加坡、泰国、马来西亚、越南、台湾、印度尼西亚、菲律宾和亚太其他地区。

由于主要市场参与者的战略举措正在大力扩张，日本有望在亚太地区占据主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势、波特五力分析和案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在对国家数据进行预测分析时，还考虑了品牌的存在和可用性以及由于来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税的影响和贸易路线。

竞争格局和亚太地区肌肉减少症治疗市场份额分析

亚太地区肌肉减少症治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、新市场计划、北美业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

该市场的一些主要市场参与者包括雅培、雀巢健康科学（雀巢公司的子公司）、诺华公司、赛诺菲、海利昂集团、巴斯夫欧洲公司、帝斯曼、Fermenta Biotech Limited、AstaReal Co., Ltd.、Metagenics、BioThrive Sciences、Wellona Pharma、The Vitamin Company India、Biogen SA、Healing Pharma India Pvt. Ltd. 等。

SKU-70291

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

表格列表

TABLE 1 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 2 ASIA-PACIFIC VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 3 ASIA-PACIFIC MEDICATINONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 4 ASIA-PACIFIC OFF-LABLE DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 5 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 6 ASIA-PACIFIC PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 7 ASIA-PACIFIC SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 8 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY STAGES , 2021-2030 (USD THOUSAND)

TABLE 9 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2021-2030 (USD THOUSAND)

TABLE 10 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY GENDER , 2021-2030 (USD THOUSAND)

TABLE 11 ASIA-PACIFIC HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 12 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL , 2021-2030 (USD THOUSAND)

TABLE 13 ASIA-PACIFIC RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL , 2021-2030 (USD THOUSAND)

TABLE 14 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 15 JAPAN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 16 JAPAN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 17 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 18 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 19 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 20 JAPAN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 21 JAPAN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 22 JAPAN PRIMARY SARCOPENIA IN SARCOPENIATREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 23 JAPAN SECONDARY SARCOPENIA IN SARCOPENIATREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 24 JAPAN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 25 JAPAN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 26 JAPAN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 27 JAPAN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 28 JAPAN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 29 JAPAN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 30 JAPAN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 31 CHINA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 32 CHINA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 33 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 34 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 35 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 36 CHINA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 37 CHINA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 38 CHINA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 39 CHINA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 40 CHINA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 41 CHINA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 42 CHINA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 43 CHINA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 44 CHINA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 45 CHINA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 46 CHINA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 47 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 48 SOUTH KOREA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 49 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 50 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 51 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 52 SOUTH KOREA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 53 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 54 SOUTH KOREA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 55 SOUTH KOREA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 56 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 57 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 58 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 59 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 60 SOUTH KOREA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 61 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 62 SOUTH KOREA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 63 INDIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 64 INDIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 65 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 66 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 67 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 68 INDIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 69 INDIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 70 INDIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 71 INDIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 72 INDIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 73 INDIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 74 INDIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 75 INDIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 76 INDIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 77 INDIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 78 INDIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 79 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 80 AUSTRALIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 81 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 82 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 83 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 84 AUSTRALIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 85 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 86 AUSTRALIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 87 AUSTRALIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 88 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 89 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 90 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 91 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 92 AUSTRALIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 93 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 94 AUSTRALIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 95 SINGAPORE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 96 SINGAPORE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 97 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 98 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 99 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 100 SINGAPORE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 101 SINGAPORE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 102 SINGAPORE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 103 SINGAPORE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 104 SINGAPORE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 105 SINGAPORE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 106 SINGAPORE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 107 SINGAPORE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 108 SINGAPORE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 109 SINGAPORE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 110 SINGAPORE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 111 THAILAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 112 THAILAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 113 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 114 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 115 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 116 THAILAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 117 THAILAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 118 THAILAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 119 THAILAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 120 THAILAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 121 THAILAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 122 THAILAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 123 THAILAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 124 THAILAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 125 THAILAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 126 THAILAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 127 MALAYSIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 128 MALAYSIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 129 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 130 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 131 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 132 MALAYSIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 133 MALAYSIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 134 MALAYSIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 135 MALAYSIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 136 MALAYSIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 137 MALAYSIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 138 MALAYSIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 139 MALAYSIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 140 MALAYSIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 141 MALAYSIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 142 MALAYSIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 143 INDONESIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 144 INDONESIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 145 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 146 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 147 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 148 INDONESIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 149 INDONESIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 150 INDONESIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 151 INDONESIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 152 INDONESIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 153 INDONESIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 154 INDONESIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 155 INDONESIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 156 INDONESIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 157 INDONESIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 158 INDONESIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 159 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 160 PHILIPPINES MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 161 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 162 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 163 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 164 PHILIPPINES VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 165 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 166 PHILIPPINES PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 167 PHILIPPINES SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 168 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 169 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 170 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 171 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 172 PHILIPPINES HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 173 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 174 PHILIPPINES RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 175 VIETNAM SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 176 VIETNAM MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 177 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 178 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 179 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 180 VIETNAM VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 181 VIETNAM SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 182 VIETNAM PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 183 VIETNAM SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 184 VIETNAM SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 185 VIETNAM SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 186 VIETNAM SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 187 VIETNAM SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 188 VIETNAM HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 189 VIETNAM SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 190 VIETNAM RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 191 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 192 NEW ZEALAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 193 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 194 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 195 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 196 NEW ZEALAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 197 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 198 NEW ZEALAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 199 NEW ZEALAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 200 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 201 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 202 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 203 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 204 NEW ZEALAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 205 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 206 NEW ZEALAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 207 TAIWAN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 208 TAIWAN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 209 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 210 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (UNITS)

TABLE 211 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD IN ASP)

TABLE 212 TAIWAN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 213 TAIWAN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 214 TAIWAN PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 215 TAIWAN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 216 TAIWAN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 217 TAIWAN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 218 TAIWAN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 219 TAIWAN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 220 TAIWAN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 221 TAIWAN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 222 TAIWAN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 223 REST OF ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

图片列表

FIGURE 1 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: MARKET END USERS COVERAGE GRID

FIGURE 8 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: SEGMENTATION

FIGURE 11 THE RISING PREVALENCE OF SARCOPENIA AND GROWING AWARENESS OF SARCOEPNIA AND ITS DETRIMENTAL EFFECT ON HEALTH ARE EXPECTED TO DRIVE THE GROWTH OF THE ASIA-PACIFIC SARCOPENIA TREATMENT MARKET FROM 2023 TO 2030

FIGURE 12 VITAMIN/DIETARY SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC SARCOPENIA MARKET IN 2023 AND 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC SARCOPENIA TREATMENT MARKET

FIGURE 14 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2022

FIGURE 15 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 16 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2023-2030)

FIGURE 17 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 18 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, 2022

FIGURE 19 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND)

FIGURE 20 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 21 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 22 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, 2022

FIGURE 23 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, 2023-2030 (USD THOUSAND)

FIGURE 24 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, CAGR (2023-2030)

FIGURE 25 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, LIFELINE CURVE

FIGURE 26 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 27 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)

FIGURE 28 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 29 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 30 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, 2022

FIGURE 31 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, 2023-2030 (USD THOUSAND)

FIGURE 32 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, CAGR (2023-2030)

FIGURE 33 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 34 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, 2022

FIGURE 35 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 36 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, CAGR (2023-2030)

FIGURE 37 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 39 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 40 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 41 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 42 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: SNAPSHOT (2022)

FIGURE 43 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET: COMPANY SHARE 2022 (%)

查看详细信息

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

How big is the Asia-Pacific Sarcopenia Treatment Market?

The Asia-Pacific Sarcopenia Treatment Market will be worth USD 861,882.42 thousand by 2030 during the forecast period.

What is the growth rate of the Asia-Pacific Sarcopenia Treatment Market?

The Asia-Pacific Sarcopenia Treatment Market growth rate is 5.9% during the forecast period.

What are the growth drivers of the Asia-Pacific Sarcopenia Treatment Market?

Rising Prevalence of Sarcopenia & Growing Awareness of Sarcopenia and its Detrimental Effects on Health are the growth drivers of the Asia-Pacific Sarcopenia Treatment Market.

What are the factors on which the Asia-Pacific Sarcopenia Treatment Market research is based on?

The treatment type, type, stages, route of administration, gender, end user, and distribution channel are the factors on which the Asia-Pacific Sarcopenia Treatment Market research is based.

Which are the major companies in the Asia-Pacific Sarcopenia Treatment Market?

Major companies in the Asia-Pacific Sarcopenia Treatment Market are Abbott., Nestlé Health Science ( A subsidary of Nestlé S.A.), Novartis AG, Sanofi, Haleon Group of Companies., BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, BioThrive Sciences., Wellona Pharma.

Forecast Period	2024 –2030
Market Size (Base Year)	USD MILLION Request
Market Size (Forecast Year)	USD 861,882.42
CAGR	5.90 %
Major Markets Players	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Request For Unlock

亚太肌肉减少症治疗市场 – 行业趋势和 2030 年预测

亚太肌肉减少症治疗市场 – 行业趋势和 2030 年预测

Asia Pacific Sarcopenia Treatment Market

CAGR : 5.90 %

亚太地区肌肉减少症治疗市场分析及规模

亚太地区肌肉减少症治疗市场动态

亚太地区肌肉减少症治疗市场范围

亚太地区肌肉减少症治疗市场区域分析/见解

竞争格局和亚太地区肌肉减少症治疗市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

报告

市场洞察

支持

解决方案

亚太肌肉减少症治疗市场 – 行业趋势和 2030 年预测

亚太肌肉减少症治疗市场 – 行业趋势和 2030 年预测

Asia Pacific Sarcopenia Treatment Market

CAGR : 5.90 %

亚太地区肌肉减少症治疗市场分析及规模

亚太地区肌肉减少症治疗市场动态

亚太地区肌肉减少症治疗市场范围

亚太地区肌肉减少症治疗市场区域分析/见解

竞争格局和亚太地区肌肉减少症治疗市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

浏览相关页面